Rivaroxaban for DVT Prophylaxis
Recommended Dosing and Duration
- The American College of Cardiology recommends rivaroxaban 10 mg once daily for DVT prophylaxis after major orthopedic surgery, initiated 6-10 hours after surgery once hemostasis is established, and continued for 10-14 days after total knee arthroplasty (TKA) or up to 35 days after total hip arthroplasty (THA) 1, 2
- For total hip arthroplasty (THA), the recommended dose is 10 mg once daily for 28-35 days 3, 4
- For total knee arthroplasty (TKA), the recommended dose is 10 mg once daily for 10-14 days 3, 4
Important Contraindications and Limitations
- Rivaroxaban is not recommended for VTE prophylaxis in acutely ill general medical patients due to unfavorable bleeding risk 1, 2
- Rivaroxaban is not recommended for prophylactic or therapeutic anticoagulation in patients with active cancer due to insufficient data in this population 5, 6
Renal Function Considerations
- Renal function is critical when prescribing rivaroxaban, as 66% of the drug undergoes renal excretion 5, 6
- Severe renal impairment (CrCl <30 mL/min) is a contraindication for rivaroxaban 5, 6
- Moderate renal impairment (CrCl 30-50 mL/min) requires caution and possible dose adjustment or alternative agent 5, 6
- Creatinine clearance must be calculated using the Cockcroft-Gault formula before initiating therapy 7, 3
Perioperative Management
- For low hemorrhagic risk procedures, discontinue rivaroxaban 3 days before the procedure when CrCl >30 mL/min 7, 3
- For high hemorrhagic risk procedures, discontinue rivaroxaban up to 5 days before the procedure, particularly for intracranial neurosurgery or neuraxial anesthesia 7, 3, 4
- No bridging therapy is required in most cases, except for very high thrombotic risk patients 7, 3, 4
Resumption After Surgery
- Prophylactic anticoagulation can be initiated with heparin (UFH or LMWH) or fondaparinux at least 6 hours after the procedure 7, 3, 4
- Rivaroxaban can be restarted at prophylactic doses within approved indications (THA or TKA) once surgical hemostasis is obtained 4, 8
Common Pitfalls to Avoid
- Do not administer rivaroxaban before adequate hemostasis is achieved post-operatively, as this significantly increases bleeding risk 1, 2
- Avoid premature discontinuation before completing the recommended duration (10-14 days for TKA, up to 35 days for THA) 1, 2
- Do not use rivaroxaban in acutely ill medical patients for VTE prophylaxis due to unfavorable bleeding risk 1, 2
- Avoid using rivaroxaban in patients with severe renal impairment (CrCl <30 mL/min) 5, 6
- Do not use rivaroxaban in cancer patients for prophylaxis or treatment until more data become available 5, 6
Comparison with Alternative Agents
- LMWH (particularly enoxaparin) remains the preferred agent for acutely ill general medical patients, patients with active cancer, and patients with severe renal impairment 1, 2, 5, 6
Rivaroxaban Recommendations and Contraindications for VTE Prophylaxis
Cancer Patients
- Rivaroxaban is not recommended for routine venous thromboembolism (VTE) prophylaxis or treatment in patients with active cancer because of insufficient supporting data. 9
- Low‑molecular‑weight heparin (e.g., enoxaparin 40 mg daily or dalteparin 5,000 U daily) or fondaparinux 2.5 mg daily remain the preferred agents for both prophylaxis and treatment in this population. 9
Acutely Ill Medical Inpatients
- In hospitalized medical patients with acute illness, LMWH (enoxaparin 40 mg daily, dalteparin 5,000 U daily) or fondaparinux 2.5 mg daily are preferred over rivaroxaban for VTE prophylaxis due to a less favorable bleeding profile with rivaroxaban. 9
Prophylaxis vs. Treatment Dosing
- The prophylactic regimen of rivaroxaban (10 mg once daily) is fundamentally different from the therapeutic regimen (15 mg twice daily for 21 days followed by 20 mg once daily). Using therapeutic doses for prophylaxis markedly increases bleeding risk without providing additional benefit. 9
Peri‑operative Management
Discontinuation Before Surgery
- Low‑bleeding‑risk procedures: Stop rivaroxaban 3 days (≈ 4 half‑lives) before the procedure when creatinine clearance (CrCl) > 30 mL/min. 10
- High‑bleeding‑risk procedures (e.g., intracranial neurosurgery, neuraxial anesthesia): Stop rivaroxaban 4–5 days before the procedure. 10